Lugano classification: Definition, Uses, and Clinical Overview

Lugano classification Introduction (What it is)

Lugano classification is a standardized way to describe the stage and treatment response of lymphoma.
It helps clinicians use the same language when reporting where lymphoma is in the body and how it is changing over time.
It is commonly used in Hodgkin lymphoma and many types of non-Hodgkin lymphoma.
It is most often applied using imaging such as PET/CT and CT, along with biopsy and clinical findings.

Why Lugano classification used (Purpose / benefits)

Cancer care depends on clear communication: what the diagnosis is, how extensive it is, and whether treatment is working. In lymphoma, the disease can involve lymph nodes, the spleen, bone marrow, and organs outside the lymphatic system (“extranodal” sites). Without a consistent framework, staging and response reporting can vary between hospitals, imaging centers, and clinical trials.

Lugano classification is used to solve several practical problems:

• Standardizing staging: It provides a shared method to describe disease extent (often summarized as Stages I–IV), which supports consistent documentation and care coordination.
• Guiding treatment planning: Stage and other descriptors (such as bulky disease or extranodal involvement) can influence whether clinicians consider treatment approaches that are more localized, more systemic, or combined. The exact approach varies by lymphoma subtype and patient factors.
• Improving response assessment: Lugano classification incorporates modern imaging—especially FDG-PET/CT for FDG-avid lymphomas—to evaluate whether lymphoma is responding, stable, or progressing.
• Supporting communication and research: Many clinical trials, guidelines, and multidisciplinary tumor boards use Lugano-based language so results and recommendations can be compared across settings.
• Helping patients understand “where things stand”: While staging can feel intimidating, a structured system can make conversations more concrete (for example, distinguishing localized from more widespread disease).

Importantly, Lugano classification does not treat lymphoma. It is a clinical and imaging-based framework used to describe lymphoma at diagnosis and over time.

Indications (When oncology clinicians use it)

Clinicians commonly apply Lugano classification in situations such as:

• A new diagnosis of lymphoma after tissue biopsy confirms the subtype
• Baseline staging before starting chemotherapy, immunotherapy, radiation therapy, or combined approaches
• Selecting an imaging approach for FDG-avid lymphomas where PET/CT is informative
• Interim (mid-treatment) response assessment when PET/CT is used to evaluate metabolic response
• End-of-treatment response assessment to document complete response, partial response, stable disease, or progression
• Suspected relapse or progression, to compare current findings with prior staging and scans
• Clinical trial enrollment, where standardized staging/response criteria are required
• Multidisciplinary planning (tumor board) across hematology-oncology, radiation oncology, radiology, pathology, and nursing teams

Contraindications / when it’s NOT ideal

Lugano classification is widely used in lymphoma, but it is not always the best fit or may need adaptation:

• Non-lymphoma cancers: Solid tumors typically use different frameworks (for example, TNM staging and RECIST response criteria).
• Lymphomas that are not reliably FDG-avid: In some indolent (slow-growing) lymphomas, PET/CT may be less informative, and CT-based measurements and clinical judgment may play a larger role.
• Conditions where PET findings can be misleading: Infection, inflammation, and recent therapies can increase FDG uptake and complicate interpretation.
• Special disease settings: Some lymphoma presentations (for example, certain central nervous system–predominant diseases) may be evaluated with additional or different criteria and imaging priorities.
• When high-quality imaging is not available: If PET/CT access is limited, clinicians may rely more heavily on CT, ultrasound, MRI in select situations, physical examination, labs, and pathology.
• When a biopsy is needed to clarify what a scan shows: Staging frameworks cannot replace tissue confirmation when diagnosis or transformation is uncertain.

When Lugano classification is not ideal, clinicians may use alternative staging or response systems, or they may adapt the approach to the lymphoma subtype and available testing.

How it works (Mechanism / physiology)

Lugano classification is not a drug or procedure with a biological “mechanism of action.” Instead, it is a clinical pathway for describing lymphoma based on:

• Anatomy (where lymphoma is located)
  Lymphoma often starts in lymph nodes and can spread through lymphatic channels. It may also involve extranodal tissues such as the gastrointestinal tract, bone marrow, liver, lungs, skin, or other organs. Lugano staging organizes findings by regions involved and whether disease is on one or both sides of the diaphragm.

• Tumor biology and imaging behavior
  Many lymphomas are FDG-avid, meaning they take up a glucose-like tracer (FDG) used in PET imaging. PET/CT highlights areas of higher metabolic activity, which often correlates with active lymphoma, though it is not perfectly specific.

• Disease burden (how much disease is present)
  CT measurements can estimate the size of lymph nodes and masses. Lugano response assessment uses changes in imaging findings (and sometimes size) to categorize response.

• Physiologic sites and organs involved
  The system considers involvement of lymph nodes, spleen, and extranodal sites. Bone marrow involvement may be assessed by imaging, biopsy, or both depending on the lymphoma type and clinical context.

Onset and duration/reversibility: These concepts do not apply in the usual way because Lugano classification does not “act” on the body. Instead, it is applied at specific timepoints (diagnosis, during treatment, after treatment) and can be updated when new clinical or imaging information becomes available.

Lugano classification Procedure overview (How it’s applied)

Lugano classification is a framework applied across the lymphoma care pathway rather than a single procedure. A common high-level workflow looks like this:

1. Evaluation and exam
   Clinicians review symptoms (such as fevers, night sweats, or weight loss), perform a physical exam (including lymph node regions), and take a detailed history.

2. Biopsy and pathology confirmation
   A tissue biopsy (often an excisional or core needle biopsy) is used to confirm lymphoma and define the subtype. Pathology, immunophenotyping, and sometimes molecular testing help classify the lymphoma.

3. Baseline imaging and labs
   Imaging often includes PET/CT for FDG-avid lymphomas and/or CT for anatomic mapping. Blood tests may assess organ function, blood counts, and other markers that support staging and treatment readiness.

4. Assigning stage and descriptors (Lugano staging)
   Clinicians integrate imaging and clinical findings to assign a stage (I–IV) and note key features such as extranodal involvement and bulky disease when relevant.

5. Treatment planning
   The care team selects an approach based on lymphoma subtype, stage, symptoms, overall health, and patient preferences. Options can include systemic therapy, radiation therapy, combined modalities, or observation in selected indolent cases. Specific regimens vary by clinician and case.

6. Intervention/therapy
   Treatment is delivered in outpatient or inpatient settings depending on the regimen and patient needs. Supportive care (anti-nausea drugs, infection prevention strategies, transfusions when needed, rehabilitation, nutrition support) is often part of the plan.

7. Response assessment (Lugano response criteria)
   Interim and/or end-of-treatment imaging assesses response. For FDG-avid lymphomas, PET/CT response is frequently summarized using standardized visual scoring (commonly the Deauville 5-point scale) and then categorized as complete metabolic response, partial response, stable disease, or progressive disease.

8. Follow-up and survivorship
   Follow-up typically includes symptom review, exam, and periodic labs and imaging as clinically indicated. The schedule and intensity vary by lymphoma subtype, prior treatment, and individual risk factors.

Types / variations

In everyday clinical use, Lugano classification is discussed in two main ways: staging and response assessment. The details are standardized, but how heavily each component is relied upon can vary by lymphoma subtype and clinical setting.

1) Lugano staging (extent of disease)

Lugano staging is commonly summarized as:

• Stage I: Limited involvement (often one lymph node region or a single extranodal site).
• Stage II: Multiple lymph node regions on the same side of the diaphragm may be involved, sometimes with limited contiguous extranodal extension.
• Stage III: Lymph node regions on both sides of the diaphragm are involved, and the spleen may be involved.
• Stage IV: More disseminated extranodal involvement (for example, bone marrow or organ involvement), depending on definitions and clinical interpretation.

Clinicians may also use modifiers and descriptors that help clarify disease pattern, such as:

• Extranodal involvement (disease outside lymph nodes)
• Bulky disease (a large mass; definitions vary by guideline and lymphoma type)
• Symptoms and risk features that influence how “limited” versus “advanced” disease is framed in treatment planning (terminology varies)

2) Lugano response assessment (how disease changes with treatment)

Response assessment in Lugano classification often incorporates:

• Metabolic response on PET for FDG-avid lymphomas (how “active” lesions look)
• Anatomic response on CT (changes in node/mass size) when PET is not used or when size changes remain important
• Categories of response, commonly described as complete response, partial response, stable disease, or progressive disease, based on standardized criteria

3) Variation by setting and population

• FDG-avid vs less FDG-avid lymphoma subtypes: PET/CT is central in many common lymphomas, but its role can be smaller in some indolent subtypes.
• Adult vs pediatric care: Many core concepts are shared, but pediatric protocols and staging/response nuances can differ by cooperative group and disease type.
• Routine practice vs clinical trials: Trials may apply criteria more strictly and at predetermined timepoints, while clinical practice may tailor imaging frequency and interpretation to the individual.

Pros and cons

Pros:

• Provides a common language for staging and response in lymphoma care
• Helps align imaging, pathology, and clinical findings into a single summary
• Supports treatment planning and risk discussion in a standardized way
• Facilitates communication across care teams (hematology-oncology, radiology, radiation oncology, pathology)
• Enables comparability in research and clinical trials
• PET-based response assessment can clarify whether residual masses are likely active disease in many FDG-avid lymphomas

Cons:

• Not equally informative for all lymphoma subtypes, especially when FDG uptake is variable
• PET/CT findings can be confounded by inflammation or infection, complicating interpretation
• Requires access to high-quality imaging and expert reading, which may vary by center
• Staging labels can feel overly simple compared with the biologic diversity of lymphoma subtypes
• Does not replace the need for biopsy when diagnosis is uncertain or transformation is suspected
• Differences in institutional practice (imaging timing, reporting style) can still lead to variability

Aftercare & longevity

Because Lugano classification is a staging and response framework—not a treatment—“aftercare” focuses on what typically happens after staging and during follow-up, and what can influence long-term outcomes in general.

Outcomes and longevity in lymphoma care are influenced by many interacting factors, including:

• Lymphoma subtype and biology (aggressive vs indolent behavior, molecular features)
• Stage and disease burden at diagnosis (localized vs advanced; bulky disease; extranodal sites)
• Response to therapy, which may be assessed using Lugano response criteria
• Treatment intensity and tolerability, including dose adjustments or delays when needed
• Supportive care and rehabilitation, such as infection monitoring, nutrition support, physical conditioning, and management of late effects
• Comorbidities (heart, lung, kidney, liver conditions; immune status)
• Follow-up consistency, including monitoring for recurrence, secondary cancers, and treatment-related complications (frequency varies by clinician and case)
• Access to specialized care, imaging, and survivorship resources

In survivorship, many patients and clinicians track symptom changes, functional recovery, emotional health, and practical concerns (work, insurance, family responsibilities). The best follow-up plan is individualized and depends on the lymphoma type and treatment received.

Alternatives / comparisons

Lugano classification is primarily compared with other ways of staging or assessing response, rather than with treatments like surgery or chemotherapy. Still, understanding alternatives can help clarify what Lugano is (and is not).

• Ann Arbor staging: Lugano staging is historically rooted in Ann Arbor concepts for lymphoma. Lugano is often described as a modernized approach that aligns staging with contemporary imaging and response assessment practices.
• RECIST (for solid tumors): RECIST is commonly used to measure response in solid cancers using tumor size changes on imaging. Lymphoma response assessment often relies more on PET metabolic response (when appropriate), which is a different concept than size-only measurement.
• Earlier lymphoma response criteria (e.g., Cheson-based approaches): Lugano represents an evolution of lymphoma response definitions, particularly with PET integration for FDG-avid disease.
• Observation/active surveillance (selected indolent lymphomas): In some slow-growing lymphomas, clinicians may monitor without immediate treatment. Lugano staging can still describe extent of disease, but treatment decisions may depend more on symptoms, organ function risk, and pace of change.
• Clinical trials and evolving criteria: Trials may incorporate Lugano while adding protocol-specific definitions, biomarker endpoints, or newer imaging strategies. Eligibility and assessment schedules vary by trial.

The “best” framework depends on the question being asked (extent at diagnosis vs response vs relapse) and the lymphoma subtype.

Lugano classification Common questions (FAQ)

Q: Is Lugano classification a test or a treatment?
It is neither a treatment nor a single test. Lugano classification is a standardized framework clinicians use to describe lymphoma stage and response to therapy. It is applied using information from biopsy, imaging (often PET/CT), and clinical evaluation.

Q: Does staging with Lugano classification hurt?
The classification itself does not cause pain. Some components used to apply it—such as blood draws, IV placement for contrast, or biopsy procedures—can cause temporary discomfort. The experience varies by the specific tests ordered and the individual.

Q: Will I need anesthesia for Lugano classification?
Not for the classification itself. Imaging like PET/CT usually does not require anesthesia, though some people may receive medication for anxiety in certain settings. Biopsies may involve local anesthesia, sedation, or (less commonly) general anesthesia depending on the biopsy type and site.

Q: What does “Stage I–IV” mean in Lugano classification?
These stages describe how widespread lymphoma appears based on lymph node regions and extranodal organ involvement. Lower stages generally indicate more localized disease, while higher stages indicate more widespread involvement. The implications vary by lymphoma subtype and other risk factors.

Q: How long does Lugano-based staging and response assessment take?
The framework is applied over time rather than in one visit. Initial staging may take days to weeks as biopsy and imaging results are completed and reviewed. Response assessments occur at planned points during or after treatment, depending on the care plan and lymphoma type.

Q: Is Lugano classification safe?
The main safety considerations relate to the tests used, especially imaging that involves radiation exposure (CT and PET/CT) and sometimes IV contrast. Clinicians generally weigh the benefit of accurate staging and response assessment against these risks. Safety considerations can differ based on age, pregnancy status, kidney function, and prior imaging history.

Q: Are there side effects from the scans used in Lugano classification?
PET/CT and CT scans can involve IV contrast, which may cause temporary sensations (warmth, metallic taste) and, rarely, allergic-type reactions. The PET tracer is typically well tolerated, but the scan process can be tiring for some people. Side effects and precautions depend on the imaging protocol and individual health factors.

Q: How much does Lugano classification cost?
There is no single cost because Lugano classification is a method, not a billable procedure on its own. Costs depend on the tests involved (biopsy type, PET/CT vs CT, lab panels), insurance coverage, and care setting. Billing and prior authorization requirements vary by region and insurer.

Q: Will staging or response scans affect my ability to work or do normal activities?
Many people return to usual activities after imaging the same day, but appointments can be time-consuming and may require fasting or schedule adjustments. If a biopsy is performed, activity limits depend on the site and technique. Your care team typically provides general post-test instructions tailored to the specific procedure.

Q: Does Lugano classification say anything about fertility?
The classification itself does not affect fertility. Fertility considerations are more directly related to the lymphoma treatment plan (some systemic therapies and radiation fields can affect reproductive organs or hormones). Discussions about fertility preservation are typically most relevant before treatment starts and vary by clinician and case.